EGFR and non-small cell lung carcinoma: Kaira et al. analyzed eleven published reports about the effectiveness of erlotinib re-challenge (may be considered as an EGFR-TKI dose-escalation) after previous gefitinib failure in advanced NSCLC patients and revealed that patients who had stable disease (SD) but not those with a complete response (CR) plus partial response (PR) or progressive disease (PD) for gefitinib benefited from erlotinib.